Wanttoexplorethefuturebeforeitbecomesheadlinenews?

MindReader is where biotech stories meet the market early. We dig into science that looks impossible at first glance, like solid tumors resisting the immune system by building invisible shields around themselves. Most investors hear about these breakthroughs after the opportunity explodes. We look before it does.

Take Replimune. Years ago, it was a small startup with one big idea: using a harmless virus to attack metastatic melanoma, a skin cancer known to spread aggressively. Scientists found that tumors that looked indestructible were surprisingly easy targets for carefully modified “oncolytic” viruses. The results? Tumors injected deep inside the body were destroyed. Even more unexpectedly, other tumors in the body started shrinking too almost like waking up a larger immune response the body had struggled to trigger on its own.

At the time, patients had almost no good treatment options, so many believed FDA approval was inevitable. The founder invested heavily approval didn’t come. The stock crashed ~80% overnight. But conviction in the science gave clarity through the noise. Instead of exiting, the position was increased 8-fold, and 60% was held as oncology experts publicly challenged the FDA decision. The rebound that followed made REPL one of the year’s most successful biotech trades, cementing why we back science.

This is the heart of MindReader: spotting early biotech innovators, decoding the real science behind them, and sharing insights that help investors see clearly, act smarter, and take confident risks without ever depending on a single voice, including ours.